3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Gastrointestinal Stromal Tumors
31
Colorectal Neoplasms
12
Pancreatic Neoplasms
11
Carcinoma, Hepatocellular
11
Stomach Neoplasms
8
Neoplasms
7
Liver Neoplasms
7
Esophageal Neoplasms
6
Carcinoma, Renal Cell
6
Neoplasm Metastasis
5
Gastrointestinal Neoplasms
5
Adenoma, Islet Cell
5
Neuroendocrine Tumors
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Carcinoma
3
Thyroid Neoplasms
2
Sarcoma
2
Rectal Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Multiple Myeloma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Digestive System Neoplasms
2
Colonic Neoplasms
2
Adenoma
2
Adenocarcinoma Of Esophagus
2
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Sunitinib
×
Gastrointestinal
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled